TESARO (NASDAQ:TSRO) had its price target reduced by Cowen from $125.00 to $80.00 in a research report report published on Tuesday, The Fly reports. They currently have a market perform rating on the biopharmaceutical company’s stock.

Other analysts also recently issued reports about the stock. HC Wainwright restated a buy rating and issued a $158.00 target price on shares of TESARO in a report on Monday, November 20th. SunTrust Banks restated a buy rating and issued a $160.00 target price on shares of TESARO in a report on Friday, November 10th. Piper Jaffray Companies restated a hold rating and issued a $80.00 target price on shares of TESARO in a report on Tuesday. Zacks Investment Research upgraded shares of TESARO from a sell rating to a hold rating in a report on Wednesday, November 8th. Finally, Argus set a $154.00 price target on shares of TESARO and gave the company a buy rating in a report on Tuesday, November 28th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $152.64.

TESARO (TSRO) traded down $0.36 on Tuesday, hitting $78.48. 157,011 shares of the company were exchanged, compared to its average volume of 1,339,667. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.35 and a current ratio of 4.73. TESARO has a 52 week low of $74.35 and a 52 week high of $192.94. The stock has a market cap of $4,270.00, a PE ratio of -9.31 and a beta of 1.51.

TESARO (NASDAQ:TSRO) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.69. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The company had revenue of $142.77 million for the quarter, compared to analysts’ expectations of $130.57 million. During the same quarter in the previous year, the company earned ($1.72) EPS. TESARO’s revenue for the quarter was up 740.3% on a year-over-year basis. equities research analysts anticipate that TESARO will post -8.18 EPS for the current year.

In other TESARO news, SVP Martin H. Jr. Huber sold 829 shares of the business’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $85.24, for a total value of $70,663.96. Following the completion of the sale, the senior vice president now directly owns 8,101 shares of the company’s stock, valued at approximately $690,529.24. The transaction was disclosed in a filing with the SEC, which is available through this link. 40.50% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. AXA boosted its position in TESARO by 89.3% in the 3rd quarter. AXA now owns 121,449 shares of the biopharmaceutical company’s stock valued at $15,679,000 after buying an additional 57,300 shares during the period. Iguana Healthcare Management LLC lifted its position in shares of TESARO by 66.7% in the 3rd quarter. Iguana Healthcare Management LLC now owns 25,000 shares of the biopharmaceutical company’s stock worth $3,228,000 after purchasing an additional 10,000 shares during the period. Neuberger Berman Group LLC lifted its position in shares of TESARO by 22.8% in the 3rd quarter. Neuberger Berman Group LLC now owns 153,540 shares of the biopharmaceutical company’s stock worth $19,822,000 after purchasing an additional 28,500 shares during the period. Bamco Inc. NY lifted its position in shares of TESARO by 30.7% in the 3rd quarter. Bamco Inc. NY now owns 13,128 shares of the biopharmaceutical company’s stock worth $1,695,000 after purchasing an additional 3,087 shares during the period. Finally, Perceptive Advisors LLC lifted its position in shares of TESARO by 8.1% in the 3rd quarter. Perceptive Advisors LLC now owns 388,651 shares of the biopharmaceutical company’s stock worth $50,175,000 after purchasing an additional 29,100 shares during the period.

WARNING: This article was originally reported by Marea Informative and is the property of of Marea Informative. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.mareainformativa.com/cowen-trims-tesaro-tsro-target-price-to-80-00/122308/.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

The Fly

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.